Hims & Hers Health, Inc. $HIMS Stock Position Lifted by Russell Investments Group Ltd.

Russell Investments Group Ltd. increased its position in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 75.6% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 46,446 shares of the company’s stock after acquiring an additional 20,003 shares during the period. Russell Investments Group Ltd.’s holdings in Hims & Hers Health were worth $2,315,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Quaker Wealth Management LLC bought a new stake in Hims & Hers Health in the second quarter worth approximately $29,000. Bessemer Group Inc. lifted its stake in shares of Hims & Hers Health by 105.8% in the 2nd quarter. Bessemer Group Inc. now owns 607 shares of the company’s stock valued at $30,000 after purchasing an additional 312 shares during the last quarter. Geneos Wealth Management Inc. bought a new stake in Hims & Hers Health in the first quarter worth $30,000. BI Asset Management Fondsmaeglerselskab A S acquired a new position in Hims & Hers Health during the first quarter worth $41,000. Finally, Spire Wealth Management bought a new position in Hims & Hers Health during the second quarter valued at about $42,000. Institutional investors own 63.52% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the company. KeyCorp started coverage on Hims & Hers Health in a research note on Tuesday, October 21st. They set a “sector weight” rating for the company. Barclays initiated coverage on Hims & Hers Health in a report on Monday. They set an “overweight” rating and a $48.00 price target on the stock. Zacks Research cut shares of Hims & Hers Health from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 19th. Wall Street Zen downgraded shares of Hims & Hers Health from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. Finally, Leerink Partnrs upgraded shares of Hims & Hers Health from a “hold” rating to a “strong-buy” rating in a report on Thursday, December 4th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, ten have assigned a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $45.50.

Insider Activity at Hims & Hers Health

In related news, insider Michael Chi sold 900 shares of the stock in a transaction dated Friday, October 10th. The shares were sold at an average price of $58.25, for a total value of $52,425.00. Following the completion of the transaction, the insider owned 291,439 shares of the company’s stock, valued at $16,976,321.75. This represents a 0.31% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Oluyemi Okupe sold 23,187 shares of the firm’s stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $36.81, for a total transaction of $853,513.47. Following the sale, the chief financial officer directly owned 70,232 shares of the company’s stock, valued at approximately $2,585,239.92. The trade was a 24.82% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 616,431 shares of company stock valued at $32,924,482 over the last quarter. 17.71% of the stock is owned by company insiders.

Hims & Hers Health Stock Up 1.4%

NYSE HIMS opened at $39.67 on Wednesday. Hims & Hers Health, Inc. has a twelve month low of $23.97 and a twelve month high of $72.98. The stock has a market cap of $9.03 billion, a PE ratio of 73.46, a PEG ratio of 7.74 and a beta of 2.41. The firm has a 50-day simple moving average of $45.02 and a 200 day simple moving average of $49.47. The company has a debt-to-equity ratio of 1.67, a quick ratio of 1.64 and a current ratio of 1.88.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings results on Monday, November 3rd. The company reported $0.06 EPS for the quarter, missing the consensus estimate of $0.09 by ($0.03). Hims & Hers Health had a net margin of 6.05% and a return on equity of 24.67%. The firm had revenue of $598.98 million during the quarter, compared to analyst estimates of $578.99 million. During the same period last year, the company earned $0.32 EPS. The company’s revenue was up 49.2% on a year-over-year basis. On average, research analysts forecast that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Hims & Hers Health declared that its board has authorized a stock repurchase program on Monday, November 17th that permits the company to buyback $250.00 million in outstanding shares. This buyback authorization permits the company to reacquire up to 3% of its shares through open market purchases. Shares buyback programs are often a sign that the company’s board of directors believes its shares are undervalued.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.